分枝杆菌生物膜：重新审视细胞外坏死病变中的结核杆菌。
Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions.
机构信息
College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Co 80524.
Wadsworth Center, NY State Department of Health and University at Albany, Albany, NY 12208.
出版信息
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0024-2016.
Abstract
Under detergent-free conditions, , the etiological agent of tuberculosis in humans, spontaneously forms organized multicellular structures called biofilms. Moreover, biofilms of are more persistent against antibiotics than their single-cell planktonic counterparts, thereby raising questions about the occurrence of biofilms in the host tissues and their significance in persistence during chemotherapy of tuberculosis. In this article, we present arguments that extracellular in necrotizing lesions likely grows as biofilms.
摘要
在无洗涤剂条件下，人类结核病的病原体分枝杆菌会自发形成称为生物膜的组织化多细胞结构。此外，分枝杆菌的生物膜比其单细胞浮游生物对应物更能抵抗抗生素，这引发了关于生物膜在宿主组织中出现及其在结核病化疗期间持续存在中的意义的问题。在本文中，我们提出了这样的论点，即在坏死病变中，细胞外分枝杆菌可能以生物膜的形式生长。
相似文献
1
Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions.
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0024-2016.
2
Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria.
Mol Microbiol. 2008 Jul;69(1):164-74. doi: 10.1111/j.1365-2958.2008.06274.x. Epub 2008 May 5.
3
Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms.
Expert Rev Anti Infect Ther. 2012 Sep;10(9):1055-66. doi: 10.1586/eri.12.88.
4
Mycobacterium biofilms: factors involved in development, dispersal, and therapeutic strategies against biofilm-relevant pathogens.
Crit Rev Eukaryot Gene Expr. 2014;24(3):269-79. doi: 10.1615/critreveukaryotgeneexpr.2014010545.
5
Mycobacterial Biofilms.
Microbiol Spectr. 2014 Oct;2(5). doi: 10.1128/microbiolspec.MGM2-0004-2013.
6
Adaptation of Mycobacterium tuberculosis to Biofilm Growth Is Genetically Linked to Drug Tolerance.
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01213-19. Print 2019 Nov.
7
Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis.
mBio. 2013 May 7;4(3):e00222-13. doi: 10.1128/mBio.00222-13.
8
Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.
Int J Mol Sci. 2024 Jul 16;25(14):7771. doi: 10.3390/ijms25147771.
9
Growth of Mycobacterium tuberculosis biofilms.
J Vis Exp. 2012 Feb 15(60):3820. doi: 10.3791/3820.
10
Drug susceptibility testing of mature Mycobacterium tuberculosis H37Ra and Mycobacterium smegmatis biofilms with calorimetry and laser spectroscopy.
Tuberculosis (Edinb). 2018 Dec;113:91-98. doi: 10.1016/j.tube.2018.09.010. Epub 2018 Oct 3.
引用本文的文献
1
Mycobacteria develop biofilms on airway epithelial cells and promote mucosal barrier disruption.
iScience. 2024 Sep 27;27(11):111063. doi: 10.1016/j.isci.2024.111063. eCollection 2024 Nov 15.
2
Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.
Int J Mol Sci. 2024 Jul 16;25(14):7771. doi: 10.3390/ijms25147771.
3
Cellulase Promotes Mycobacterial Biofilm Dispersal in Response to a Decrease in the Bacterial Metabolite Gamma-Aminobutyric Acid.
Int J Mol Sci. 2024 Jan 15;25(2):1051. doi: 10.3390/ijms25021051.
4
Bacterial biofilms in the human body: prevalence and impacts on health and disease.
Front Cell Infect Microbiol. 2023 Aug 30;13:1237164. doi: 10.3389/fcimb.2023.1237164. eCollection 2023.
5
Polyphosphate kinase 1 is involved in formation, the morphology and ultramicrostructure of biofilm of and its survivability in macrophage.
Heliyon. 2023 Mar 17;9(3):e14513. doi: 10.1016/j.heliyon.2023.e14513. eCollection 2023 Mar.
6
biofilms.
Biofilm. 2023 Feb 7;5:100107. doi: 10.1016/j.bioflm.2023.100107. eCollection 2023 Dec.
7
Antibiotic Resistance to and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents.
Antibiotics (Basel). 2022 Oct 18;11(10):1431. doi: 10.3390/antibiotics11101431.
8
Imidazole-Thiosemicarbazide Derivatives as Potent Anti- Compounds with Antibiofilm Activity.
Cells. 2021 Dec 9;10(12):3476. doi: 10.3390/cells10123476.
9
Stringent Response in Mycobacteria: From Biology to Therapeutic Potential.
Pathogens. 2021 Nov 1;10(11):1417. doi: 10.3390/pathogens10111417.
10
and Formation and Treatment of Mixed Biofilm .
Front Cell Infect Microbiol. 2021 Nov 1;11:681131. doi: 10.3389/fcimb.2021.681131. eCollection 2021.
本文引用的文献
1
Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis.
Tuberculosis (Edinb). 2016 Mar;97:8-17. doi: 10.1016/j.tube.2015.11.010. Epub 2016 Jan 2.
2
Postprimary Tuberculosis and Macrophage Necrosis: Is There a Big ConNECtion?
mBio. 2016 Jan 12;7(1):e01589-15. doi: 10.1128/mBio.01589-15.
3
The association between sterilizing activity and drug distribution into tuberculosis lesions.
Nat Med. 2015 Oct;21(10):1223-7. doi: 10.1038/nm.3937. Epub 2015 Sep 7.
4
Mathematical Model of Oxygen Transport in Tuberculosis Granulomas.
Ann Biomed Eng. 2016 Apr;44(4):863-72. doi: 10.1007/s10439-015-1415-3. Epub 2015 Aug 8.
5
Intracellular Bacterial Communities: A Potential Etiology for Chronic Lower Urinary Tract Symptoms.
Urology. 2015 Sep;86(3):425-31. doi: 10.1016/j.urology.2015.04.002. Epub 2015 Jul 15.
6
Second generation 2-aminoimidazole based advanced glycation end product inhibitors and breakers.
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4820-4823. doi: 10.1016/j.bmcl.2015.06.080. Epub 2015 Jun 29.
7
Mass spectrometry imaging of levofloxacin distribution in TB-infected pulmonary lesions by MALDI-MSI and continuous liquid microjunction surface sampling.
Int J Mass Spectrom. 2015 Feb 1;377:699-708. doi: 10.1016/j.ijms.2014.08.024.
8
Mycobacterial Biofilms.
Microbiol Spectr. 2014 Oct;2(5). doi: 10.1128/microbiolspec.MGM2-0004-2013.
9
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30.
10
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.
Immunol Rev. 2015 Mar;264(1):288-307. doi: 10.1111/imr.12252.
Zotero 插件